Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
Academic rigor, journalistic flair
Articles on Pharmaceutical industry
Displaying 1 - 20 of 51 articles
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
Some commercial products and practices are directly linked to avoidable ill health, planetary damage, and social and health inequity. Large transnational corporations are especially to blame.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Changes to Canada’s Patented Medicine Prices Review Board regulations have been postponed for a fourth time in two years as Canadians continue to pay some of the highest drug prices in the world.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
If no action is taken to address antibiotic resistance, infections from multidrug-resistant bacteria could cause 10 million deaths each year by 2050.
New payment models may mean more of the people who need these treatments can get them.
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
If Big Pharma wants to achieve the ultimate image makeover, it must capitalize on the current public good will about its COVID-19 vaccines by prioritizing socially responsible practices.
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Waiver talks might convince companies to focus on technology transfer and training, and let go of the plan to maximise patent-based revenues.
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
A vaccination queue-jumping scandal in Peru has caused a massive uproar in the South American country. It could also be a wake-up call for all nations.
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
A private market should have no place in the rollout of a COVID vaccine.
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
Top contributors
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, Bond University
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Director of the Health Law Institute at the Schulich School of Law, Dalhousie University
-
Professor of Health Economics, Queen's University Belfast
-
Professor of Health Economics, Flinders University
-
Professor of Economics, University of Calgary
-
Adjunct Professor, Australian Centre for Health Law Research, School of Law, Queensland University of Technology
-
Palliative Medicine Physician, Senior Research Fellow, The University of Melbourne
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Lecturer in Criminology, University of Auckland
-
Reader in Intellectual Property Law, City, University of London
-
Associate Professor of Public Policy and Women's Studies, University of Michigan
-
Associate Professor in the SAMRC Centre for Health Economics and Decision Science - PRICELESS SA (Priority Cost Effective Lessons in Systems Strengthening South Africa), University of the Witwatersrand
-
Associate professor, School of Public Health, University of Alberta
